Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 1, 2014, Pages 29-41

  Yan, Jun Wei ^a   Wang, Yu Jie ^a   Peng, Wen Jia ^a   Tao, Jin Hui ^a   Wan, Ya Nan ^a   Li, Bao Zhu ^a   Mei, Bin ^a   Chen, Bing ^a   Yao, Hua ^a   Yang, Guo Jun ^a   Li, Xiang Pei ^a   Ye, Dong Qing ^a   Wang, Jing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Autoimmune diseases; IL 17; IL 17 receptor; Inflammation; Therapy

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; ADALIMUMAB; BRODALUMAB; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; CEL 2000; CELASTROL; ES 62; ETANERCEPT; GRAPE SEED EXTRACT; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 25; IXEKIZUMAB; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; NK 007; QUETIAPINE; RAPAMYCIN; RITUXIMAB; SECUKINUMAB; SULFORAPHANE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALPHA HELIX; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNE DISEASE; CANDIDIASIS; CELL DIFFERENTIATION; CELL MIGRATION; CHAGAS DISEASE; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOSE RESPONSE; HEPATITIS; HUMAN; INFLAMMATION; LIVER INJURY; LUNG FIBROSIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOCHEMOTHERAPY; PNEUMONIA; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; RNA STABILITY; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH17 CELL; UPREGULATION;

AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; INTERLEUKIN-17;

EID: 84890366022     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.843669     Document Type: Review

References (126)

1. Vazquez-Tello A, Halwani R, Li R, et al. IL-17A and IL-17F expression in B lymphocytes. Int Arch Allergy Immunol 2012;157:406-16
2. Shibui A, Shimura E, Nambu A, et al. Th17 cell-derived IL-17 is dispensable for B cell antibody production. Cytokine 2012;59:108-14
3. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009;11:625-30
4. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013;published online on 3 June 2013; doi:10.1517/13543784. 2013.806483
5. Gradolatto A, Nazzal D, Foti M, et al. Defects of immunoregulatory mechanisms in myasthenia gravis: Role of IL-17. Ann NY Acad Sci 2012;1274:40-7
6. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012;11:763-76
7. Puel A, Cypowyj S, Marodi L, et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012;12:616-22
8. Rubino SJ, Geddes K, Girardin SE. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol 2012;33:112-18
9. Tournadre A, Miossec P. Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep 2012;14:252-6
10. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: Mechanisms and therapeutic potential. Clin Sci (Lond) 2012;122:487-511
11. Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: From cutaneous immunobiology to clinical application. Clin Immunol 2013;146:131-9
12. Ahmed M, Gaffen SL. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev 2010;21:449-53
13. Chiricozzi A, Zhang S, Dattola A, et al. Role of Th17 in the pathogenesis of cutaneous inflammatory diseases. J Biol Regul Homeost Agents 2012;26:313-18
14. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 1995;155:5483-6
15. Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/ 17A heterodimer in activated human CD4+ T cells. J Biol Chem 2007;282:13447-55
16. Grailer JJ, Bosmann M, Ward PA. Regulatory effects of C5a on IL-17A, IL-17F, and IL-23. Front Immunol 2012;3:387
17. Novatchkova M, Leibbrandt A, Werzowa J, et al. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 2003;28:226-9
18. Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine 2013;62:175-82
19. Zhang B, Liu C, Qian W, et al. Crystal structure of IL-17 receptor B SEFIR domain. J Immunol 2013;190:2320-6
20. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-Alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87
21. Wang YH, Voo KS, Liu B, et al. A novel subset of CD4(+) T(H)2 memory/ effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med 2010;207:2479-91
22. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012;64:99-109
23. Gladiator A, Wangler N, Trautwein-Weidner K, et al. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J Immunol 2013;190:521-5
24. Satoh T, Tajima M, Wakita D, et al. The development of IL-17/IFN-gammadouble producing CTLs from Tc17 cells is driven by epigenetic suppression of Socs3 gene promoter. Eur J Immunol 2012;42:2329-42
25. Bermejo DA, Jackson SW, Gorosito-Serran M, et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol 2013;14:514-22
26. Yang R, Liu Y, Kelk P, et al. A subset of IL-17(+) mesenchymal stem cells possesses anti-Candida albicans effect. Cell Res 2013;23:107-21
27. Nagai S, Kurebayashi Y, Koyasu S. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. Ann NY Acad Sci 2013;1280:30-4
28. Jordan-Williams KL, Poston S, Taparowsky EJ. BATF regulates the development and function of IL-17 producing iNKT cells. BMC Immunol 2013;14:16
29. Ward FJ, Dahal LN, Wijesekera SK, et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol 2013;43:1274-85
30. Sun X, Shibata K, Yamada H, et al. CD30L/CD30 is critical for maintenance of IL-17A-producing gamma delta T cells bearing Vgamma6 in mucosa-Associated tissues in mice. Mucosal Immunol 2013;published on line 3 April 2013; doi: 10.1038/mi.2013.18
31. Zhang MA, Rego D, Moshkova M, et al. Peroxisome proliferator-Activated receptor (PPAR)alpha and -gamma regulate IFNgamma and IL-17A production by human T cells in a sex-specific way. Proc Natl Acad Sci USA 2012;109:9505-10
32. Kurai D, Nakagaki K, Wada H, et al. Mycoplasma pneumoniae extract induces an IL-17-Associated inflammatory reaction in murine lung: Implication for mycoplasmal pneumonia. Inflammation 2013;36:285-93
33. Henderson MW, Inatsuka CS, Sheets AJ, et al. Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation. Infect Immun 2012;80:2061-75
34. Bhan U, Newstead MJ, Zeng X, et al. TLR9-dependent IL-23/IL-17 is required for the generation of Stachybotrys chartarum-induced hypersensitivity pneumonitis. J Immunol 2013;190:349-56
35. Silverpil E, Wright AK, Hansson M, et al. Negative feedback on IL-23 exerted by IL-17A during pulmonary inflammation. Innate Immun 2013;published online 7 January 2013; doi: 10.1177/1753425912470470
36. Wozniak KL, Kolls JK, Wormley FL Jr. Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by gamma/delta T cells. BMC Immunol 2012;13:65
37. Mukherjee S, Allen RM, Lukacs NW, et al. STAT3-mediated IL-17 production by postseptic T cells exacerbates viral immunopathology of the lung. Shock 2012;38:515-23
38. Hou L, Jie Z, Desai M, et al. Early IL-17 production by intrahepatic T cells is important for adaptive immune responses in viral hepatitis. J Immunol 2013;190:621-9
39. Tosello Boari J, Amezcua Vesely MC, Bermejo DA, et al. IL-17RA signaling reduces inflammation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils. PLoS Pathog 2012;8:e1002658
40. Wang B, Zhao XP, Fan YC, et al. IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. Antiviral Res 2013;97:285-92
41. Zhang Y, Chen L, Gao W, et al. IL-17 neutralization significantly ameliorates hepatic granulomatous inflammation and liver damage in Schistosoma japonicum infected mice. Eur J Immunol 2012;42:1523-35
42. Glocker EO, Grimbacher B. Mucosal antifungal defence: IL-17 signalling takes centre stage. Immunol Cell Biol 2011;89:823-5
43. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-Associated cytokines IL-17 and IL-22. J Invest Dermatol 2008;128:2640-5
44. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8
45. Varga J AD. Systemic sclerosis: A prototype multisystem fibrotic disorder. 2007;117:557-67
46. Naraghi K, van Laar JM. Update on stem cell transplantation for systemic sclerosis: Recent trial results. Curr Rheumatol Rep 2013;15:326
47. Bayry J, Radstake TR. Immune-mediated inflammatory diseases: Progress in molecular pathogenesis and therapeutic strategies. Expert Rev Clin Immunol 2013;9:297-9
48. Wu Y, Zhu L, Wei H, et al. Regulation of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and extracellular metalloproteinase inducer by interleukin-17 in human periodontal ligament fibroblasts. J Endod 2013;39:62-7
49. Bellini A, Marini MA, Bianchetti L, et al. Interleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunol 2012;5:140-9
50. Hayashi H, Kawakita A, Okazaki S, et al. IL-17A/F Modulates Fibrocyte Functions in Cooperation with CD40-Mediated Signaling. Inflammation 2013;published online 12 February; doi: 10.1007/s10753-013-9609-
51. Wang W, Fan YQ, Lv Z, et al. Interleukin-25 promotes basic fibroblast growth factor expression by human endothelial cells through interaction with IL-17RB, but not IL-17RA. Clin Exp Allergy 2012;42:1604-14
52. Meng F, Wang K, Aoyama T, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012;143:765-76; e1-3
53. Hara M, Kono H, Furuya S, et al. Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. J Surg Res 2013;published online 28 March 2013; doi: 10.1016/j. jss.2013.03.025
54. Hasan SA, Eksteen B, Reid D, et al. Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis. J Allergy Clin Immunol 2013;131:1663-73
55. Liu Y, Zhu H, Su Z, et al. IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCbeta/Erk1/2/NFkappaB- dependent signaling pathway. Int Immunol 2012;24:605-12
56. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-63
57. Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease. J Dermatol Sci 2008;50:240-2
58. Truchetet ME, Brembilla NC, Montanari E, et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 2013;65:1347-56
59. Truchetet ME, Allanore Y, Montanari E, et al. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. Ann Rheum Dis 2012;71:2044-50
60. Truchetet ME, Brembilla NC, Montanari E, et al. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: Association with interstitial lung disease. Arthritis Res Ther 2011;13:R166
61. Hasegawa M, Fujimoto M, Matsushita T, et al. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2013;52:242-51
62. Haavardsholm EA, Lie E, Lillegraven S. Should modern imaging be part of remission criteria in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2012;26:767-85
63. Lee SY, Kwok SK, Son HJ, et al. IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther 2013;15:R31
64. Li G, Zhang Y, Qian Y, et al. Interleukin-17A promotes rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing MMP2 and MMP9 expression through NF-kappaB/HIF-1alpha pathway. Mol Immunol 2013;53:227-36
65. Li GQ, Zhang Y, Liu D, et al. Celastrol inhibits interleukin-17A- stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression. Int Immunopharmacol 2012;14:422-31
66. Abdollahi-Roodsaz S, de Loo FA, Koenders MI, et al. Destructive role of myeloid differentiation factor 88 and protective role of TRIF in interleukin-17-dependent arthritis in mice. Arthritis Rheum 2012;64:1838-47
67. Park JS, Park MK, Lee SY, et al. TWEAK promotes the production of Interleukin-17 in rheumatoid arthritis. Cytokine 2012;60:143-9
68. Hazlett J, Stamp LK, Merriman T, et al. IL-23R rs11209026 polymorphism modulates IL-17A expression in patients with rheumatoid arthritis. Genes Immun 2012;13:282-7
69. Tian Y, Shen H, Xia L, et al. Elevated Serum and Synovial Fluid Levels of Interleukin-34 in Rheumatoid Arthritis: Possible Association with Disease Progression Via Interleukin-17 Production. J Interferon Cytokine Res 2013; published online 19 February 2013; doi:10.1089/jir.2012.0122
70. Baek SH, Lee SG, Park YE, et al. Increased synovial expression of IL-27 by IL-17 in rheumatoid arthritis. Inflamm Res 2012;61:1339-45
71. Balani D, Aeberli D, Hofstetter W, et al. Interleukin-17A stimulates granulocyte-macrophage colonystimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. Arthritis Rheum 2013;65:436-46
72. Ruddy MJ, Shen F, Smith JB, et al. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: Implications for inflammation and neutrophil recruitment. J Leukoc Biol 2004;76:135-44
73. Noto LM, Sarnacki SH, Vazquez MV, et al. Salmonella enterica induces joint inflammation and expression of interleukin-17 in draining lymph nodes early after onset of enterocolitis in mice. Infect Immun 2012;80:2231-9
74. Pineda MA, McGrath MA, Smith PC, et al. The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum 2012;64:3168-78
75. Mok MY, Wu HJ, Lo Y, et al. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 2010;37:2046-52
76. Tanasescu C, Balanescu E, Balanescu P, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med 2010;21:202-7
77. Oh SH, Roh HJ, Kwon JE, et al. Expression of interleukin-17 is correlated with interferon-Alpha expression in cutaneous lesions of lupus erythematosus. Clin Exp Dermatol 2011;36:512-20
78. Torricelli M, Bellisai F, Novembri R, et al. High levels of maternal serum IL-17 and activin A in pregnant women affected by systemic lupus erythematosus. Am J Reprod Immunol 2011;66:84-9
79. Hedrich CM, Crispin JC, Rauen T, et al. cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci USA 2012;109:16606-11
80. Robak E, Kulczycka-Siennicka L, Gerlicz Z, et al. Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients. Eur Cytokine Netw 2013;24:60-8
81. Chatterjee M, Hedrich CM, Rauen T, et al. CD3-T cell receptor co-stimulation through SLAMF3 and SLAMF6 receptors enhances RORgammat recruitment to the IL17A promoter in human T lymphocytes. J Biol Chem 2012;287:38168-77
82. Wen Z, Xu L, Xu W, et al. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One 2013;8:e58161
83. Zhang J, Zhang Y, Zhang L, et al. Epistatic Interaction between Genetic Variants in Susceptibility Gene ETS1 Correlates with IL-17 Levels in SLE Patients. Ann Hum Genet 2013;published online 24 April 2013; doi: 10.1111/ahg.12018
84. Wang X, Lin Z, Wei Q, et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009;29:1343-7
85. Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 2011;30:269-73
86. Chen WS, Chang YS, Lin KC, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc 2012;75:303-8
87. Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:ii116-23
88. Huh JR, Leung MW, Huang P, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgt activity. Nature 2011;472:486-90
89. Makino Y, Yamaza H, Akiyama K, et al. Immune therapeutic potential of stem cells from human supernumerary teeth. J Dent Res 2013;92:609-15
90. Pickens SR, Chamberlain ND, Volin MV, et al. Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization. Angiogenesis 2011;14:443-55
91. Chen DY, Chen YM, Chen HH, et al. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-A therapy. Arthritis Res Ther 2011;13:R126
92. Alzabin S, Abraham SM, Taher TE, et al. Incomplete response of infl ammatory arthritis to TNF-Alpha blockade is associated with the Th17 pathway. Ann Rheum Dis 2012;71:1741-8
93. Queiroz-Junior CM, Bessoni RL, Costa VV, et al. Preventive and therapeutic anti-TNF-Alpha therapy with pentoxifylline decreases arthritis and the associated periodontal co-morbidity in mice. Life Sci 2013;published online 2 August 2013; doi: 10.1016/j. lfs.2013.07.022
94. Li X, Chen L, Wu Z, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-Alpha therapy. J Clin Immunol 2013;33:151-61
95. McGovern JL, Nguyen DX, Notley CA, et al. Th17 cells are restrained by regulatory T cells from patients responding to anti-TNF antibody therapy via inhibition of IL-6. Arthritis Rheum 2012;64:3129-38
96. Yue C, You X, Zhao L, et al. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010;30:1553-7
97. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011;63:1507-16
98. Li Y, Jiang L, Zhang S, et al. Methotrexate attenuates the Th17/IL- 17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int 2012;32:2415-22
99. Shen H, Xia L, Lu J, et al. Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med 2010;58:905-8
100. Yao Y, Ding C, Fang Y. Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats. Rheumatol Int 2013;33:1845-53
101. Chen L, Wang C, Leng N, et al. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011;31:596-605
102. Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: Rationale and clinical potential Ther Adv Musculoskelet Dis 2013;5:141-52
103. Hueber WD, Patel D, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17a, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72
104. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum 2010;62:929-39
105. Lin J, Xiao L, Ouyang G, et al. Total glucosides of paeony inhibits Th1/ Th17 cells via decreasing dendritic cells activation in rheumatoid arthritis. Cell Immunol 2012;280:156-63
106. Cho ML, Heo YJ, Park MK, et al. Grape seed proanthocyanidin extract (GSPE) attenuates collagen-induced arthritis. Immunol Lett 2009;124:102-10
107. Park MK, Park JS, Cho ML, et al. Grape seed proanthocyanidin extract (GSPE) differentially regulates Foxp3(+) regulatory and IL-17(+) pathogenic T cell in autoimmune arthritis. Immunol Lett 2011;135:50-8
108. Tanaka M, Okamoto Y, Fukui T, et al. Suppression of interleukin 17 production by Brazilian propolis in mice with collagen-induced arthritis. Inflammopharmacology 2012;20:19-26
109. Kim H, Bang J, Chang HW, et al. Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol 2012;678:55-60
110. Casca?o R, Vidal B, Raquel H, et al. Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun Rev 2012;11:856-62
111. Venkatesha SH, Yu H, Rajaiah R, et al. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. J Biol Chem 2011;286:15138-46
112. Kong JS, Yoo SA, Kim HS, et al. Inhibition of synovial hyperplasia, rheumatoid T cell activation, and experimental arthritis in mice by sulforaphane, a naturally occurring isothiocyanate. Arthritis Rheum 2010;62:159-70
113. Haruta K, Mori S, Tamura N, et al. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. Inflamm Res 2012;61:551-62
114. Zimmerman DH, Taylor P, Bendele A, et al. CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/ chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int Immunopharmacol 2010;10:412-21
115. Wen T, Li Y, Wu M, et al. Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor alpha production and Th17 cell differentiation. Arthritis Rheum 2012;64:2896-906
116. Akashi N, Matsumoto I, Tanaka Y, et al. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Mod Rheumatol 2011;21:267-75
117. Yoshizaki A, Yanaba K, Yoshizaki A, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010;62:2476-87
118. Furuzawa-Carballeda J, Ortíz-Á valos M, Lima G, et al. Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)- 17A, IL-22 and transforming growth factor-b1 expression, and increases Foxp3-expressing cells in localized scleroderma. Clin Exp Dermatol 2012;37:599-609
119. Papp G, Horvath IF, Barath S, et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 2012;142:150-9
120. Wu HY, Quintana FJ, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol 2008;181:6038-50
121. Hou LF, He SJ, Li X, et al. SM934 treated lupus-prone NZB NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One 2012;7:e32424
122. Hou LF, He SJ, Li X, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 2011;63:2445-55
123. Kang HK, Ecklund D, Liu M, et al. Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res Ther 2009;11:R59
124. Lai K, Zeng K, Zeng F, et al. Allogeneic adipose-derived stem cells suppress Th17 lymphocytes in patients with active lupus in vitro. Acta Biochim Biophys Sin (Shanghai) 2011;43:805-12
125. Rizzo A, Losacco A, Carratelli CR, et al. Lactobacillus plantarum reduces Streptococcus pyogenes virulence by modulating the IL-17, IL-23 and Toll-like receptor 2/4 expressions in human epithelial cells. Int Immunopharmacol 2013;17:453-61
126. Kusagaya H, Fujisawa T, Yamanaka K, et al. TLR-Mediated Airway IL-17C Enhances Epithelial Host Defense in an Autocrine/Paracrine Manner. Am J Respir Cell Mol Biol 2013;published on line 14 August 2013; doi: 10.1165/rcmb.2013- 0130OC